Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sutent in advanced unresectable neuroendocrine tumor
NCT00056693Phase 2Completed
- Sponsor
- Pfizer
- Start
- Apr 2003
- Primary completion
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in Neuroendocrine Neoplasm (NEN), sponsored by Pfizer. Primary endpoint: Objective Response Rate. Started Apr 2003; status: completed.
02
Drugs
sunitinib
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT00056693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00056693.